Početna › B-stanični limfom › Utah
Kliničke studije za B-stanični limfom u državi Utah
8 studija za B-stanični limfom traži sudionike na lokacijama u državi Utah.
Gradovi u državi Utah
Službeni tekst studije (engleski)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Intermountain Health, Canyons Region, LDS Hospital, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06343311A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Intermountain Healthcare, Salt Lake City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07101328A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Primary Children's Hospital, Salt Lake City
U tijeku regrutacijaFaza 1
Od 0 do 18 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT06173518A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Huntsman Cancer Institute, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06634589Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT07188558A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Utah, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. stu 2025. · NCT05643742Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Primary Children's Hospital, Salt Lake City
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. pro 2024. · NCT05476770Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.